MAP2K7 and Alzheimer disease: Although we did not rule out the possibility that protective effect of trametinib in AD is via other ERK-dependent mechanisms in non-neuronal cells, we clearly showed that MEK inhibition by trametinib provides neuronal protection from Aβ burden by increasing autophagic lysosomal activity through TFEB activation in models of AD.